Lupin and Sandoz launch Ranluspec ranibizumab biosimilar across Europe following EC approval

Lupin and commercial partner Sandoz have begun launching Ranluspec, a ranibizumab biosimilar, across European markets excluding Germany, expanding commercial competition in treatments for retinal vascular diseases.

Lupin announced on 12 November 2026 that Sandoz had launched Ranluspec, Lupin's ranibizumab biosimilar, in European markets excluding Germany following an existing European Commission marketing authorisation covering vial and pre-filled syringe presentations for approved ophthalmic indications.

Ranluspec targets vascular endothelial growth factor A and is intended for retinal conditions including neovascular age-related macular degeneration, diabetic macular oedema and macular oedema associated with retinal vein occlusion, with the announcement marking commercial market entry rather than a newly granted European Commission approval.

Field	Content
Article Type	Industry Updates
Developer	Lupin
Commercial Partner	Sandoz
Product	Ranluspec
Active Ingredient	Ranibizumab
Product Classification	Biosimilar
Reference Medicine Class	Anti-VEGF ophthalmic therapy
Molecular Target	Vascular endothelial growth factor A
Target Abbreviation	VEGF-A
Announcement Date	12 November 2026
Event Type	European commercial biosimilar launch
Launch Status	Announced
Geographic Scope	European markets excluding Germany
Explicitly Excluded Market	Germany
Regulatory Basis	Existing European Commission marketing authorisation
New European Commission Approval	No
Available Presentation One	Vial
Available Presentation Two	Pre-filled syringe
Therapeutic Area	Ophthalmology
Indication One	Neovascular age-related macular degeneration
Indication One Abbreviation	nAMD
Indication Two	Diabetic macular oedema
Indication Three	Macular oedema associated with retinal vein occlusion
Treatment Mechanism	VEGF-A inhibition
Commercialisation Responsibilities	Sandoz commercial launch
Developer Responsibilities	Lupin developed the biosimilar
Product Pricing	Not disclosed in supplied summary
Market Share Expectations	Not disclosed
What Happened	Lupin announced the European commercial launch of its ranibizumab biosimilar through Sandoz.
Why It Matters	The launch adds biosimilar competition in retinal disease treatment markets and may expand purchasing and treatment options.
Commercial Significance	Moves an already authorised biosimilar into European commercial distribution.
Regulatory Clarification	The event is a market launch following existing approval rather than a new European Commission marketing authorisation.
Geographic Clarification	Germany is explicitly excluded from the announced European launch footprint.
Key Takeaway	Sandoz has launched Lupin's Ranluspec across European markets other than Germany.
What to Watch	Country-level availability, reimbursement, pricing, uptake, competition and potential future expansion into additional markets.
Primary Source	Lupin
Primary Source URL	https://www.lupin.com/media/press-releases/lupin-announces-european-launch-of-biosimilar-ranibizumab
Relevant Date	12 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com